top of page

Multiple myeloma-New treatments 11/10/2026

Amit Garg
6 days ago
1 min read

1. Major phase 3 myeloma results: teclistamab + talquetamab


Johnson & Johnson announced positive phase 3 results for the combination of teclistamab (Tecvayli) and talquetamab (Talvey) in relapsed/refractory multiple myeloma.

  • Combines BCMA and GPRC5D targeting

  • Studied as early as second-line treatment

  • Company reports reduced disease progression and death risk compared with standard care

  • Detailed efficacy and safety results are expected at ASH 2026


Why it matters: Dual-target bispecific therapy could potentially move earlier in the myeloma treatment algorithm. We still need the absolute PFS benefit, toxicity data, and mature overall survival results. But these results are exciting

 
 
 

Recent Posts

See All
5 Lab clues you are Iron Deficient

 1. Ferritin<30 ng/mL. Ferritin<100 ng/mL if inflammation, autoimmune diseases, cancer 2. Low transferrin saturation (TSAT) <20% suggests insufficient circulating iron availability 3. MCV <80 indicate

 
 
 

Comments


bottom of page